Salarius Pharmaceuticals Inc Stock Price, News & Analysis

Salarius Pharmaceuticals (Nasdaq: SLRX) confirmed that its common stock continues to trade on the Nasdaq under the ticker SLRX after identifying inaccurate delisting information on the S&P CapIQ platform.

On Nov 13, 2025 the company completed an underwritten public offering raising gross proceeds of $8 million and closed its merger with Decoy Therapeutics; the combined company reports pro forma cash of approximately $14 million and about 5.9 million shares outstanding.

Salarius said it is advancing Decoy’s peptide conjugate pipeline and expects to pursue an IND filing within 12 months for a pan-coronavirus antiviral.

Salarius Pharmaceuticals (Nasdaq: SLRX) and Decoy Therapeutics completed a strategic merger on November 13, 2025, creating a combined company to be renamed Decoy Therapeutics.

The combined business will advance Decoy’s IMP3ACT™ platform that uses AI/ML and high-speed synthesis to design and manufacture peptide conjugate therapeutics. The merger yields pro forma cash of $14 million following the closing and a recent public offering. Management will be led by Decoy founders including CEO Frederick Pierce and CSO Barbara Hibner, with Mark Rosenblum remaining CFO.

The company expects to advance its lead pan-coronavirus antiviral to an IND filing within 12 months and progress programs for broad-acting respiratory antivirals and a peptide drug conjugate for GI cancers.

Salarius Pharmaceuticals (NASDAQ: SLRX) priced an underwritten public offering to raise approximately $7.0 million of gross proceeds through the sale of 2,514,335 common shares and pre-funded warrants for 2,152,331 shares, each accompanied by Series A and Series B warrants covering up to a combined 4,666,666 shares per warrant series. The combined public price is $1.50 per share with warrants and $1.4999 per pre-funded warrant with warrants.

The offering includes a 45-day underwriter option for up to 699,999 additional units, is managed by Ladenburg Thalmann, and is expected to close on or about November 12, 2025, subject to closing conditions including completion of the proposed business combination with Decoy Therapeutics. Net proceeds are expected to fund clinical development, repay certain Decoy promissory notes, and support general corporate purposes.

Salarius Pharmaceuticals (Nasdaq: SLRX) announced it regained compliance with Nasdaq Listing Rule 5550(b)(1) on October 10, 2025, completing compliance with all Nasdaq listing requirements after earlier regaining the Minimum Bid Price rule on September 9, 2025.

The company reiterated its planned business combination with Decoy Therapeutics, originally announced in a definitive merger agreement dated January 13, 2025; under the agreement Decoy will merge with a Salarius subsidiary and the combined company will be named Decoy Therapeutics.

Nasdaq also notified Salarius it will be subject to a Mandatory Panel Monitor for one year from October 10, 2025, and that a renewed breach during that period could trigger a delisting determination with a hearing opportunity.

Salarius Pharmaceuticals (Nasdaq: SLRX) has regained compliance with Nasdaq's Minimum Bid Price Requirement (Rule 5550(a)(2)) as of September 4, 2025. The company still needs to meet the Equity Standard Requirement (Rule 5550(b)(1)) by October 20, 2025 to maintain its listing.

SLRX will be under a Mandatory Panel Monitor for one year starting September 4, 2025. Additionally, the company has previously announced a definitive merger agreement with Decoy Therapeutics on January 13, 2025. Post-merger, the combined entity will operate as Decoy Therapeutics, focusing on developing peptide conjugate therapeutics.

Salarius Pharmaceuticals (NASDAQ: SLRX), a clinical-stage biopharmaceutical company, has announced a 1-for-15 reverse stock split effective August 15, 2025. The split aims to regain compliance with Nasdaq's minimum $1.00 bid price requirement.

Following the split, SLRX's outstanding shares will reduce from approximately 7.6 million to 509,000 shares. Trading on a split-adjusted basis will begin August 18, 2025, under a new CUSIP number 79400X503. The split will uniformly affect all stockholders, with cash provided for fractional shares based on the August 15 closing price.

The reverse split was approved by stockholders on July 8, 2025, and will adjust all outstanding options, warrants, and shares reserved under the 2015 Employee Stock Purchase Plan accordingly.

Salarius Pharmaceuticals (Nasdaq: SLRX) has received an additional extension from Nasdaq to regain compliance with two critical listing requirements by late July/early August 2025. The company must meet the $2.5 million minimum stockholders' equity requirement and the $1.00 minimum bid price requirement to maintain its Nasdaq listing.

This extension follows Salarius' January 2025 announcement of a definitive merger agreement with Decoy Therapeutics, a private preclinical biopharmaceutical company. Upon completion, the merged entity will operate as Decoy Therapeutics, focusing on peptide conjugate therapeutics development.

Salarius Pharmaceuticals (NASDAQ:SLRX) announced supporting evidence for its first-in-class LSD1 inhibitor seclidemstat (SP-2577) from two recently published animal studies. The drug is currently being evaluated in a Phase 1/2 clinical study at MD Anderson Cancer Center for treating myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).

The studies, published in peer-reviewed journals, demonstrate seclidemstat's role in inhibiting LSD1, a validated target in cancer treatment. The company expects to provide updates on the clinical trial later in 2025. Additionally, Salarius continues to progress with its planned merger with Decoy Therapeutics, announced in January 2025, which will result in the formation of a new company named Decoy Therapeutics.

Decoy Therapeutics announces that MIT Professor and Moderna co-founder Robert S. Langer will join their Scientific Advisory Board following the completion of their merger with Salarius Pharmaceuticals (NASDAQ: SLRX). The appointment comes after the January 13, 2025 merger agreement announcement between the companies.

Dr. Langer, a renowned scientist and entrepreneur, brings extensive experience in drug delivery systems and tissue engineering. His pioneering work has contributed to breakthrough medicines like Roche's Avastin and Moderna's Spikevax COVID vaccine. As an MIT Institute Professor with over 1,600 scientific papers and 400+ company patent licenses, Dr. Langer will support Decoy's development of novel peptide-conjugate therapeutics through their proprietary IMP3ACT™ platform.